WO2000073276A3 - Carboxylic acid derivatives comprising aryl-substituted nitrogen heterocycles, their production and their use as endothelin receptor antagonists - Google Patents

Carboxylic acid derivatives comprising aryl-substituted nitrogen heterocycles, their production and their use as endothelin receptor antagonists Download PDF

Info

Publication number
WO2000073276A3
WO2000073276A3 PCT/EP2000/004571 EP0004571W WO0073276A3 WO 2000073276 A3 WO2000073276 A3 WO 2000073276A3 EP 0004571 W EP0004571 W EP 0004571W WO 0073276 A3 WO0073276 A3 WO 0073276A3
Authority
WO
WIPO (PCT)
Prior art keywords
carboxylic acid
acid derivatives
production
receptor antagonists
aryl
Prior art date
Application number
PCT/EP2000/004571
Other languages
German (de)
French (fr)
Other versions
WO2000073276A2 (en
Inventor
Wilhelm Amberg
Georg Kettschau
Original Assignee
Basf Ag
Wilhelm Amberg
Georg Kettschau
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to IL14680000A priority Critical patent/IL146800A0/en
Priority to CA002375666A priority patent/CA2375666A1/en
Priority to JP2000621342A priority patent/JP2003500476A/en
Priority to BR0011105-8A priority patent/BR0011105A/en
Application filed by Basf Ag, Wilhelm Amberg, Georg Kettschau filed Critical Basf Ag
Priority to SK1755-2001A priority patent/SK17552001A3/en
Priority to PL00355112A priority patent/PL355112A1/en
Priority to AU53959/00A priority patent/AU765345B2/en
Priority to EP00938660A priority patent/EP1181281A2/en
Priority to MXPA01012284A priority patent/MXPA01012284A/en
Priority to KR1020017015482A priority patent/KR20020006049A/en
Publication of WO2000073276A2 publication Critical patent/WO2000073276A2/en
Publication of WO2000073276A3 publication Critical patent/WO2000073276A3/en
Priority to NO20015762A priority patent/NO20015762L/en
Priority to BG106154A priority patent/BG106154A/en
Priority to HK02108677.1A priority patent/HK1047102A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/30—Only oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention relates to carboxylic acid derivatives of formula (I), whereby the substituents have the meanings as explained in the description. The invention also relates to the production and use of said novel carboxylic acid derivatives as endothelin receptor antagonists.
PCT/EP2000/004571 1999-06-01 2000-05-19 Carboxylic acid derivatives comprising aryl-substituted nitrogen heterocycles, their production and their use as endothelin receptor antagonists WO2000073276A2 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
PL00355112A PL355112A1 (en) 1999-06-01 2000-05-19 Carboxylic acid derivatives comprising aryl-substituted nitrogen heterocycles, their production and their use as endothelin receptor antagonists
JP2000621342A JP2003500476A (en) 1999-06-01 2000-05-19 Novel carboxylic acid derivatives having an aryl-substituted nitrogen heterocycle, their preparation and their use as endothelin receptor antagonists
BR0011105-8A BR0011105A (en) 1999-06-01 2000-05-19 Carboxylic acid derivative, use of a combination derivative, and pharmaceutical preparation for oral, parenteral or intraperitoneal use
EP00938660A EP1181281A2 (en) 1999-06-01 2000-05-19 Novel carboxylic acid derivatives comprising aryl-substituted nitrogen heterocycles, their production and their use as endothelin receptor antagonists
SK1755-2001A SK17552001A3 (en) 1999-06-01 2000-05-19 Carboxylic acid derivatives comprising aryl-substituted nitrogen heterocycles, their production and their use as endothelin receptor antagonists
CA002375666A CA2375666A1 (en) 1999-06-01 2000-05-19 Novel carboxylic acid derivatives comprising aryl-substituted nitrogen heterocycles, their production and their use as endothelin receptor antagonists
AU53959/00A AU765345B2 (en) 1999-06-01 2000-05-19 Novel carboxylic acid derivatives comprising aryl-substituted nitrogen heterocycles, their production and their use as endothelin receptor antagonists
IL14680000A IL146800A0 (en) 1999-06-01 2000-05-19 Novel carboxylic acid derivatives comprising aryl-substituted nitrogen heterocycles, their preparation and use as endothelin receptor antagonists
MXPA01012284A MXPA01012284A (en) 1999-06-01 2000-05-19 Novel carboxylic acid derivatives comprising aryl-substituted nitrogen heterocycles, their production and their use as endothelin receptor antagonists.
KR1020017015482A KR20020006049A (en) 1999-06-01 2000-05-19 Novel Carboxylic Acid Derivatives Comprising Aryl-Substituted Nitrogen Heterocycles, Their Production and Their Use as Endothelin Receptor Antagonists
NO20015762A NO20015762L (en) 1999-06-01 2001-11-26 New carboxylic acid derivatives with aryl-substituted nitrogen heterocycles, their preparation and use
BG106154A BG106154A (en) 1999-06-01 2001-11-27 Carboxylic acid derivatives comprising aryl-substituted nitrogen heterocycles, methods for their production and their use as endothelin receptor antagonists
HK02108677.1A HK1047102A1 (en) 1999-06-01 2002-11-29 Novel carboxylic acid derivatives comprising aryl-substituted nitrogen heterocycles, their production and their use as endothelin receptor antagonists

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19924892.3 1999-06-01
DE19924892A DE19924892A1 (en) 1999-06-01 1999-06-01 New carboxylic acid derivatives with aryl-substituted nitrogen heterocycles, their production and use as endothelin receptor antagonists

Publications (2)

Publication Number Publication Date
WO2000073276A2 WO2000073276A2 (en) 2000-12-07
WO2000073276A3 true WO2000073276A3 (en) 2001-05-10

Family

ID=7909761

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/004571 WO2000073276A2 (en) 1999-06-01 2000-05-19 Carboxylic acid derivatives comprising aryl-substituted nitrogen heterocycles, their production and their use as endothelin receptor antagonists

Country Status (20)

Country Link
EP (1) EP1181281A2 (en)
JP (1) JP2003500476A (en)
KR (1) KR20020006049A (en)
CN (1) CN1359376A (en)
AR (1) AR022047A1 (en)
AU (1) AU765345B2 (en)
BG (1) BG106154A (en)
BR (1) BR0011105A (en)
CA (1) CA2375666A1 (en)
CZ (1) CZ20014312A3 (en)
DE (1) DE19924892A1 (en)
HK (1) HK1047102A1 (en)
HU (1) HUP0201387A3 (en)
IL (1) IL146800A0 (en)
MX (1) MXPA01012284A (en)
NO (1) NO20015762L (en)
PL (1) PL355112A1 (en)
SK (1) SK17552001A3 (en)
TR (1) TR200103475T2 (en)
WO (1) WO2000073276A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2011147232A (en) * 2009-04-22 2013-05-27 Астеллас Фарма Инк. CARBONIC ACID DERIVATIVE

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998027070A1 (en) * 1996-12-18 1998-06-25 Basf Aktiengesellschaft Heterocyclic carboxylic acid derivatives, the production and use thereof as endothelin receptor antagonists
DE19726146A1 (en) * 1997-06-19 1998-12-24 Basf Ag New ß-amino and ß-azidopcarboxylic acid derivatives, their preparation and use as endothelin receptor antagonists
WO1999011629A1 (en) * 1997-09-04 1999-03-11 Basf Aktiengesellschaft Novel carboxylic acid derivatives, their production and their use as mixed eta/etb endothelin-receptor antagonists
DE19806438A1 (en) * 1998-02-17 1999-08-19 Basf Ag New pyrimidinyloxy-propionic acid derivatives useful as endothelin receptor antagonists in treatment of e.g. cardiac insufficiency, restenosis, hypertension, kidney failure, asthma and prostate cancer
DE19809144A1 (en) * 1998-03-04 1999-09-09 Basf Ag New asymmetrically substituted carboxylic acid derivatives, their preparation and use as mixed ET¶LAMBDA¶ / ET¶B¶ receptor antagonists
DE19836044A1 (en) * 1998-08-10 2000-02-17 Basf Ag New 2-(hetero)aryl-alkanoic acid derivatives, useful as mixed endothelin receptor antagonists, e.g. for treating cardiac insufficiency, restenosis, hypertension or prostate cancer

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998027070A1 (en) * 1996-12-18 1998-06-25 Basf Aktiengesellschaft Heterocyclic carboxylic acid derivatives, the production and use thereof as endothelin receptor antagonists
DE19726146A1 (en) * 1997-06-19 1998-12-24 Basf Ag New ß-amino and ß-azidopcarboxylic acid derivatives, their preparation and use as endothelin receptor antagonists
WO1998058916A1 (en) * 1997-06-19 1998-12-30 Basf Aktiengesellschaft NEW β-AMINO AND β-AZIDOCARBOXYLIC ACID DERIVATIVES, THE PRODUCTION THEREOF AND THE USE THEREOF AS ENDOTHELIN RECEPTOR ANTAGONISTS
WO1999011629A1 (en) * 1997-09-04 1999-03-11 Basf Aktiengesellschaft Novel carboxylic acid derivatives, their production and their use as mixed eta/etb endothelin-receptor antagonists
DE19806438A1 (en) * 1998-02-17 1999-08-19 Basf Ag New pyrimidinyloxy-propionic acid derivatives useful as endothelin receptor antagonists in treatment of e.g. cardiac insufficiency, restenosis, hypertension, kidney failure, asthma and prostate cancer
DE19809144A1 (en) * 1998-03-04 1999-09-09 Basf Ag New asymmetrically substituted carboxylic acid derivatives, their preparation and use as mixed ET¶LAMBDA¶ / ET¶B¶ receptor antagonists
DE19836044A1 (en) * 1998-08-10 2000-02-17 Basf Ag New 2-(hetero)aryl-alkanoic acid derivatives, useful as mixed endothelin receptor antagonists, e.g. for treating cardiac insufficiency, restenosis, hypertension or prostate cancer

Also Published As

Publication number Publication date
CN1359376A (en) 2002-07-17
PL355112A1 (en) 2004-04-05
KR20020006049A (en) 2002-01-18
CZ20014312A3 (en) 2003-02-12
BG106154A (en) 2002-08-30
EP1181281A2 (en) 2002-02-27
TR200103475T2 (en) 2002-04-22
CA2375666A1 (en) 2000-12-07
JP2003500476A (en) 2003-01-07
HUP0201387A3 (en) 2004-12-28
DE19924892A1 (en) 2000-12-07
HK1047102A1 (en) 2003-02-07
HUP0201387A2 (en) 2002-08-28
AR022047A1 (en) 2002-09-04
MXPA01012284A (en) 2002-07-30
SK17552001A3 (en) 2002-08-06
NO20015762D0 (en) 2001-11-26
BR0011105A (en) 2002-03-05
NO20015762L (en) 2001-12-13
WO2000073276A2 (en) 2000-12-07
AU5395900A (en) 2000-12-18
IL146800A0 (en) 2002-07-25
AU765345B2 (en) 2003-09-18

Similar Documents

Publication Publication Date Title
AU2002350961A1 (en) Ethylene diamine derivatives and their use as orexin-receptor antagonists
HK1039930A1 (en) Piperazine derivatives useful as ccr5 antagonists.
WO2002010140A3 (en) Imidazolyl derivatives
MXPA02008402A (en) Derivatives of quinoline as alpha-2 antagonists.
WO2003059903A3 (en) Substituted 4-aminopyridine derivatives used as pest control agents
AU1783201A (en) 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors
EP1244452A4 (en) Urotensin-ii receptor antagonists
AU1626001A (en) 3,4-dihydro-(1h)-quinazolin-2-ones and their use as csbp/p38 kinase inhibitors
AU1781601A (en) 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors
BG104022A (en) New beta-amino and beta-azidocarboxylic acid derivatives, the production thereof and the use thereof as endothelin receptor antagonists
BG103502A (en) Heterocyclic derivatives of carboxylic acids, their preparation and application as endothelial receptor antagonists
WO2000073276A3 (en) Carboxylic acid derivatives comprising aryl-substituted nitrogen heterocycles, their production and their use as endothelin receptor antagonists
AU2673201A (en) Alpha-arylethylpiperazine derivatives as neurokinin antagonists
CA2372664A1 (en) Substituted benzimidazole, the production thereof and the use thereof as means against parasitic protozoa
BG104222A (en) Novel carboxylic acid derivatives, their production and their use as mixed eta/etb endothelin-receptor antagonists
AU3027199A (en) 5-substituted pyrimidine-2-yloxy carboxylic acid derivatives, the production of the same and their utilization as endothelin antagonists
MXPA04001977A (en) Ccr-3 receptor antagonists v.
WO2003045917A3 (en) Ccr-3 receptor antagonists vii
BG105618A (en) Beta-amido and beta-sulphonamide derivatives of carboxylic acids, method for preparation and application as endothelin-receptor antagonists
BG106321A (en) Novel carboxylic acid derivatives with 5,6- substituted pyrimidine ring, the production and utilization thereof as endothelin receptor antagonists
BG105236A (en) New carboxylic acid derivatives carrying keto side-chains, their production and use as endothelin-receptor antagonists
WO2000075119A3 (en) Substituted 2-aryl-1,2,4-triazine-3,5-di(thi)ones used as herbicides
AU2001268490A1 (en) Dihydrostilbene alkanoic acid derivatives useful as vitronectin antagonists
WO2001000188A3 (en) Tetrahydroquinolinyl-6-methyldihydrothiadiazinone derivatives and their use for preventing and/or treating anaemia
AU2001231744A1 (en) Novel carboxylic acid derivatives containing alkyl substituted triazines, production of the same and use thereof as endothelin receptor antagonists

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 00809738.0

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2000 106154

Country of ref document: BG

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 200109725

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/012284

Country of ref document: MX

Ref document number: IN/PCT/2001/1687/CHE

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2375666

Country of ref document: CA

Ref document number: 2375666

Country of ref document: CA

Kind code of ref document: A

Ref document number: 2000 621342

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 515860

Country of ref document: NZ

Ref document number: 17552001

Country of ref document: SK

Ref document number: PV2001-4312

Country of ref document: CZ

Ref document number: 2000938660

Country of ref document: EP

Ref document number: 2001/03475

Country of ref document: TR

WWE Wipo information: entry into national phase

Ref document number: 1020017015482

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: P20010941A

Country of ref document: HR

WWE Wipo information: entry into national phase

Ref document number: 53959/00

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2001 2001135870

Country of ref document: RU

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 1020017015482

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2000938660

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2001-4312

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: 53959/00

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 2000938660

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1020017015482

Country of ref document: KR